ROTE WILLIAM E. — SEC insider filings

SEC reporting owner CIK 1698262. 33 insider filings on record with FilingPulse; latest filed 2026-09-17.

Transaction summary — filings shown

Covers all 33 filings on record, filed 2020-09-22 to 2026-09-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Travere Therapeutics, Inc. (TVTX)Chief Research Officer33—42 legs · 365,493 sh · $17,961,91543

Insider filings — ROTE WILLIAM E.

FiledFormIssuerReported transactionsSource
2026-09-174Travere Therapeutics, Inc. (TVTX)Option exercise (M): 39,000 @ $25.25 · Option exercise (M): 39,650 @ $17.96 · Sale (S): 63,907 @ $61.99 · Sale (S): 29,021 @ $62.66 · Sale (S): 3,000 @ $63.65 · Sale (S): 270 @ $65.31 · +10 moreEDGAR
2026-05-064Travere Therapeutics, Inc. (TVTX)Option exercise (M): 4,250 @ $0 · Sale (S): 2,763 @ $43.95 · Grant/award (A): 8,500 (derivative) @ $0 · Option exercise (M): 4,250 (derivative) @ $0EDGAR
2026-04-234Travere Therapeutics, Inc. (TVTX)Sale (S): 9,100 @ $39.09EDGAR
2026-04-154Travere Therapeutics, Inc. (TVTX)Grant/award (A): 14,000 @ $0EDGAR
2026-02-034Travere Therapeutics, Inc. (TVTX)Grant/award (A): 20,090 @ $0 · Sale (S): 12,446 @ $32.87 · Grant/award (A): 53,570 (derivative) @ $0EDGAR
2025-12-294Travere Therapeutics, Inc. (TVTX)Option exercise (M): 60,000 @ $20.61 · Sale (S): 60,000 @ $40.10 · Option exercise (M): 60,000 (derivative) @ $0EDGAR
2025-05-054Travere Therapeutics, Inc. (TVTX)Option exercise (M): 4,920 · Sale (S): 3,198 @ $21.05 · Option exercise (M): 4,920 (derivative) @ $0EDGAR
2025-02-124Travere Therapeutics, Inc. (TVTX)Option exercise (M): 8,000 · Sale (S): 5,200 @ $23.53 · Option exercise (M): 8,000 (derivative) @ $0EDGAR
2025-02-044Travere Therapeutics, Inc. (TVTX)Grant/award (A): 21,500 @ $0 · Sale (S): 8,951 @ $19.78 · Grant/award (A): 58,000 (derivative) @ $0EDGAR
2025-01-234Travere Therapeutics, Inc. (TVTX)Sale (S): 2,437 @ $19.46EDGAR
2024-09-094Travere Therapeutics, Inc. (TVTX)Grant/award (A): 6,750 @ $0 · Sale (S): 4,387 @ $11.52EDGAR
2024-02-024Travere Therapeutics, Inc. (TVTX)Grant/award (A): 25,000 @ $0 · Sale (S): 2,174 @ $8.53 · Sale (S): 2,590 @ $8.86 · Grant/award (A): 65,000 (derivative) @ $0EDGAR
2024-01-254Travere Therapeutics, Inc. (TVTX)Sale (S): 2,062 @ $8.96EDGAR
2023-09-054Travere Therapeutics, Inc. (TVTX)Grant/award (A): 3,300 @ $0 · Sale (S): 1,815 @ $14.71EDGAR
2023-05-124Travere Therapeutics, Inc. (TVTX)Sale (S): 825 @ $16.59EDGAR
2023-02-024Travere Therapeutics, Inc. (TVTX)Grant/award (A): 20,250 @ $0 · Sale (S): 2,590 @ $22.25 · Grant/award (A): 54,500 (derivative) @ $0 · Grant/award (A): 6,750 (derivative) @ $0EDGAR
2023-01-264Travere Therapeutics, Inc. (TVTX)Sale (S): 2,062 @ $21.50EDGAR
2022-05-124Travere Therapeutics, Inc. (TVTX)Sale (S): 750 @ $21.93 · Sale (S): 813 @ $21.52EDGAR
2022-02-024Travere Therapeutics, Inc. (TVTX)Grant/award (A): 9,840 @ $0 · Sale (S): 1,125 @ $27.40 · Grant/award (A): 39,360 (derivative) @ $0 · Grant/award (A): 9,840 (derivative) @ $0 · Grant/award (A): 8,000 (derivative) @ $0EDGAR
2022-01-264Travere Therapeutics, Inc. (TVTX)Sale (S): 1,875 @ $24.98EDGAR
2022-01-124Travere Therapeutics, Inc. (TVTX)Grant/award (A): 5,000 @ $0 · Sale (S): 2,500 @ $27.40EDGAR
2021-08-174Travere Therapeutics, Inc. (TVTX)Grant/award (A): 4,500 @ $0 · Sale (S): 1,407 @ $17.12EDGAR
2021-05-134Travere Therapeutics, Inc. (TVTX)Sale (S): 1,563 @ $19.14 · Sale (S): 1,562 @ $19.46EDGAR
2021-02-184Travere Therapeutics, Inc. (TVTX)Sale (S): 1,250 @ $27.35 · Sale (S): 1,250 @ $28.67EDGAR
2021-02-094Travere Therapeutics, Inc. (TVTX)Sale (S): 2,250 @ $31.41 · Sale (S): 2,250 @ $31.58EDGAR
2021-02-054Travere Therapeutics, Inc. (TVTX)Grant/award (A): 4,500 @ $0EDGAR
2021-02-034Travere Therapeutics, Inc. (TVTX)Sale (S): 2,500 @ $28.91 · Sale (S): 1,125 @ $28.91EDGAR
2021-02-024Travere Therapeutics, Inc. (TVTX)Grant/award (A): 5,000 @ $0 · Sale (S): 2,500 @ $30.75 · Sale (S): 1,125 @ $30.75EDGAR
2021-01-254Travere Therapeutics, Inc. (TVTX)Grant/award (A): 15,000 @ $0 · Grant/award (A): 57,500 (derivative) @ $0EDGAR
2020-11-174Travere Therapeutics, Inc. (RTRX)Sale (S): 2,500 @ $23.96EDGAR
2020-11-134Retrophin, Inc. (RTRX)Grant/award (A): 5,000 @ $0 · Sale (S): 2,500 @ $23.62EDGAR
2020-09-234Retrophin, Inc. (RTRX)Sale (S): 1,500 @ $18.48EDGAR
2020-09-224Retrophin, Inc. (RTRX)Grant/award (A): 3,000 @ $0 · Sale (S): 1,500 @ $18.59EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-09-21 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1698262 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs